Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Plus Therapeutics Secures Medicare Enrollment for CNSide Diagnostics, Opening Reimbursement Access to Half the U.S. Medicare Population

In the diagnostics industry, clinicalUtilityalone does not generate revenue. A laboratory test or assay platform becomes commercially viable only when it can be billed to payers, and Medicare enrollment is the essential first step in that process. For Plus Therapeutics' CNSide Diagnostics subsidiary, the …

Nitish Kishor | 07 May 2026

Entrada Therapeutics: ELEVATE-44-201 Delivers Statistically Significant DMD Functional Benefit as TRDA Suffers a Brutal Single-Session Collapse

Duchenne muscular dystrophy is among the most serious and well-characterized rare genetic diseases affecting children globally. Caused by mutations in the dystrophin gene, DMD leads to progressive muscle degeneration, loss of independent ambulation, and eventual cardiorespiratory failure. The condition disproportionately affects young males, and …

Nitish Kishor | 07 May 2026

Apyx Medical Beats Q1 Revenue and EBITDA Estimates, Raises Full-Year Guidance as APYX Surges 25%

Apyx Medical occupies a distinctive position in the medical technology landscape as the developer of Renuvion, a helium plasma-based energy delivery platform cleared by the FDA for use in multiple aesthetic and surgical body contouring applications. Unlike the clinical-stage companies in this sector, Apyx …

Nitish Kishor | 07 May 2026

Coinbase Q1 2026 Earnings Preview: Will COIN Stock Rise or Fall After Results Tonight?

When Coinbase Global steps up to report its first-quarter 2026Earningsafter Thursday's closing bell, it will do so under conditions that few at the company would have chosen. A prolonged slump inCryptocurrency Trading, a workforce reduction that rattled employees earlier this week, a damning preview …

Nitish Kishor | 07 May 2026

McDonald's Q1 Beat Exposes a Consumer Spending Paradox Across Global Markets

Beating Estimates in a Quarter Nobody Expected to Be Easy

Nitish Kishor | 07 May 2026

Insulet Q1 2026: Strong Earnings Beat Masks Margin Pressure and Retention Risks

Insulet Corporation (Nasdaq:PODD) beat Q1 2026Earningsexpectations with 34%Revenuegrowth and a 40% EPS surge, yet shares fell nearly 10%. Here is what the numbers reveal.Key HighlightsQ1 2026 revenue rose 34% year-over-year to USD 761.7 million, exceeding the analyst consensus of USD 728.36 million.Adjusted EPS of …

Nitish Kishor | 07 May 2026

TransMedics Earnings Miss: Can Aggressive Growth Bets Justify Margin Pain?

Revenue Growth Intact, Profitability Under Strain

Nitish Kishor | 07 May 2026

US Exports Hit Record USD 320.9 Billion: Can the Momentum Hold?

US exports hit a record USD 320.9 billion in March 2026, but energy price effects andTariff-drivenImportfront-loading cloud the outlook. An analytical breakdown of what the data actually signals.Key HighlightsUS goods and services exports rose 2.0% to a record USD 320.9 billion in March 2026.Energy …

Nitish Kishor | 07 May 2026
Support

Hi! How can we help you today?

Loading…